The role of the CD44 cell surface molecule in tumorigenesis has been the focus of intense debate. Now enough pieces are known to begin putting the puzzle together.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nanotechniques Inactivate Cancer Stem Cells
Nanoscale Research Letters Open Access 15 June 2017
-
Heparan sulfate proteoglycans undergo differential expression alterations in right sided colorectal cancer, depending on their metastatic character
BMC Cancer Open Access 20 October 2015
-
Aberrant caspase-activated DNase (CAD) transcripts in human hepatoma cells
British Journal of Cancer Open Access 28 January 2003
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gunthert, U. et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13–24 (1991).
Role of CD44 in the pathogenesis of CNS malignancies (special issue on CD44). J. Neuro-Oncol. (in the press).
Hofmann, M. et al. CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res. 51, 5295–5297 (1991).
Matsumura, Y. & Tarin, D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340, 1053–1058 (1992).
Stamenkovic, I., Aruffo, A. & Seed, B. The hemopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J. 10, 343–348 (1991).
Dougherty, G.J., Lansdorp, P.M., Cooper, D.L. & Humphries, R.K. Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte “homing” receptor expressed by hemopoietic cells. J. exp. Med. 174, 1–5 (1991).
Cooper, D.L. et al. The complex CD44 transcrip-tiortal unit: Alternative splicing of three internal exons generates the epithelial form of CD44. Biochem. Biophys. res. Commun. 182, 569–578 (1992).
Screaton, G.R., Bell, M.V., Jackson, D.G., Cornelis, F.B., Gerth, U. & Bell, J.I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. natn. Acad. Set U.S.A. 89, 12160–12164 (1992).
Tanabe, K.K., Ellis, L.M. & Saya, H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 341, 725–726 (1993).
Tarin, D. et al. The clinical significance of malfunction of the CD44 locus in malignancy. J. Neuro-Oncol. (in the press).
Dougherty, G.J., Dougherty, S.T., Eaves, C.J. & McBride, W.H. Expression of human CD44R1 enhances the metastatic capacity of murine fibrosarcoma cells. Proc. Am. Assoc. Cancer Res. 33, 35 (1992).
Seiter, S. et al. Prevention of tumor metastasis formation by anti-variant CD44. J. exp. Med. 177, 443–455 (1993).
Merzak, A., Koocheckpour, S. & Pilkington, G.J. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res. 54, 3988–3992 (1994).
Aruffo, A., Stamenkovic, I., Melnick, M., Under-hill, C.B. & Seed, B. CD44 is the principle cell surface receptor for hyaluronate. Cell 61, 1303–1313 (1990).
Miyake, K., Underhill, C.B., Lesley, J. & Kincade, P.W. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J. exp. Med. 172, 69–75 (1990).
Toyama-Sorimachi, N. et al. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J. biol. Chem. 270, 7437–7444 (1995).
Naujokas, M.F., Morin, M., Anderson, M.S., Peterson, M. & Miller, J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74, 257–268 (1993).
Dougherty, G.J., Cooper, D.L., Memory, J.F. & Chiu, R.K. Ligand binding specificity of alternatively spliced CD44 isoforms. Recognition and binding of hyaluronan by CD44R1. J. biol Chem. 269, 9074–9078 (1994).
Droll, A. et al. Adhesive Interactions between alternatively spliced CD44 isoforms. J. biol Chem. 270, 11567–11573 (1995).
Jackson, D.G., Bell, J.I., Dickinson, R., Timans, J., Shields, J. & Whittle, N. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. cell Biol. 128, 673–685 (1995).
Bennett, K.L. et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J. cell Biol. 128, 687–698(1995).
Labarriere, N. et al. H blood group antigen carried by CD44V modulates tumorigenicity of rat colon carcinoma cells. Cancer Res. 54, 6275–6281 (1994).
Asman, D.C. et al. Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA Alternative splicing as a VDEPT control element. J. Neuro-Oncol. (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cooper, D., Dougherty, G. To metastasize or not? Selection of CD44 splice sites. Nat Med 1, 635–637 (1995). https://doi.org/10.1038/nm0795-635
Issue Date:
DOI: https://doi.org/10.1038/nm0795-635
This article is cited by
-
Nanotechniques Inactivate Cancer Stem Cells
Nanoscale Research Letters (2017)
-
Heparan sulfate proteoglycans undergo differential expression alterations in right sided colorectal cancer, depending on their metastatic character
BMC Cancer (2015)
-
Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma
International Journal of Clinical Oncology (2013)
-
Alternative splicing of SYK regulates mitosis and cell survival
Nature Structural & Molecular Biology (2011)
-
Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion
Cancer Chemotherapy and Pharmacology (2008)
